Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

CTLT reports Q3 revenue decline, eyes growth in gene therapy

CTLT faced challenges in the Biologics segment and adjusted its fiscal 2023 guidance due to operational and COVID-related issues. However, the company's capacity and healthy pipeline in the gene therapy business present opportunities for growth. The company is also evaluating divestitures to reduce debt load and is focused on improving financial rigor in the upcoming fiscal year.

Catalent reports solid Q2 earnings, eyes gene therapy expansion

Catalent's Q2 performance was solid, with a focus on collaborations, ESG initiatives, and strong market positioning. Challenges in the supply chain and COVID revenue assumptions were notable, but opportunities in gene therapy and core business growth are promising. The company remains optimistic about future growth and strategic partnerships.

Catalent adjusts guidance, targets cost savings amid operational challenges

Catalent focused on improving productivity and cost structure to return to historical margin levels.
Addressing investor concerns on regulatory inspections and confident in corrective actions.
Expecting significant cost savings in fiscal '24 and targeting positive cash generation.
Operational challenges in Q3 impacting financials in Q4, with a focus on improving profitability.

Catalent addresses challenges, eyes growth in gene therapy and GLP-1

Catalent navigated fiscal challenges, focusing on growth areas like gene therapy and GLP-1 projects. The company aims to address financial performance, operational efficiency, and strategic reviews to enhance shareholder value and sustain growth.

Catalent reports solid Q1 performance amidst revenue challenges and growth opportunities

Catalent's Q1 performance was solid despite revenue decline from COVID.
The company is focusing on growth drivers like gene therapy and GLP-1 demand.
Challenges include revenue concentration risks and capacity constraints.
Opportunities lie in new business wins, tech transfer completion, and strategic improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced financial results for the third quarter of fiscal 2021, which ended March 31, 2021. “I am proud of Catalent's robust third-quarter results and excited by the strong foundation we've built for continued growth, through the dedication and ing

Catalent, Inc. Reports Third Quarter Fiscal 2021 Results

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene and cell therapies, and consumer health products, today announced that it will release financial results for the third quarter of fiscal year 2021 ended March 31, 2021, before the market open on Tuesday, May 4, 2021. The Company's management will host a webcast to discuss the results at 8:15 a.m. ET on th

Catalent, Inc. Announces Third Quarter Fiscal Year 2021 Earnings Conference Webcast

Moderna

Catalent (CTLT) expands its collaboration with Moderna to provide a new high-speed vial filling line for the manufacture of the latter's COVID-19 vaccine.

Catalent (CTLT) Expands Deal With Moderna for COVID-19 Vaccine

CAMBRIDGE, Mass. & SOMERSET, N.J.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced the expansion of their strategic collaboration to dedicate a new high-speed vial filling line for the ma

Moderna and Catalent Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna's COVID-19 Vaccine and Clinical Portfolio

Catalent Inc (NYSE: CTLT) is reportedly expanding its U.S. production of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine to ensure the U.S. has ample supply as it ramps up vaccinations. Catalent helps Moderna fill its vaccine in vials for shipment.

Catalent To Boost Output Of Finished Vials For Moderna's COVID-19 Shot: WSJ

Catalent Inc. , a contract drug manufacturer, is expanding U.S. production of the COVID-19 vaccine developed by Moderna Inc. and will nearly double production at its Bloomington, Ind. plant to about 400 vials a minute in April, the Wall Street Journal reported Tuesday, citing people familiar with the matter.

Contract drug maker Catalent to double production of Moderna COVID vaccine: WSJ

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).

Time to Focus on Catalent (CTLT) for Strong Earnings Growth Potential

Johnson & Johnson

Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine is expected to get a significant supply boost after manufacturing partner Catalent Inc (NYSE: CTLT) secured a key U.S. regulator clearance, Bloomberg News reported on Tuesday. What Happened: A U.S. Food and Drug Administration's emergency-use clearance received Tuesday will allow Catalent's facility in Bloomington, Indiana, to manufacture and ship millions of doses helping boost the vaccination supply.

J&J COVID-19 Vaccine To Get Supply Boost As Manufacturing Partner Catalent Secures Key FDA Clearance

TORONTO--(BUSINESS WIRE)--Cybin signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

Chewy

Salesforce

Amplify Cybersecurity ETF

Innovator Loup Frontier Tech ETF

Oracle

Pool

Despite occasional pullbacks in share price, these growth stocks are expected to continue to create shareholder value during the year. The post 7 Growth Stocks With Compelling Stories appeared first on InvestorPlace.

7 Growth Stocks With Compelling Stories

Catalent is scaling up manufacturing capacity for Johnson & Johnson's COVID-19 vaccine at its Italian plant, addressing some concerns over the drugmaker's ability to meet vaccine supply targets in the European Union.

Catalent to ramp up J&J vaccine production at Italian plant

Catalent Inc plans to expand its COVID-19 vaccine production in Europe that will enable it to make more doses of Johnson & Johnson's shot, the Wall Street Journal reported https://www.wsj.com/articles/catalent-to-expand-production-of-j-j-covid-19-vaccine-in-italy-11615941463?mod=latest_headlines on Tuesday, citing people familiar with the matter.

Catalent plans to expand production of J&J COVID-19 vaccine in Italy: WSJ

Catalent (CTLT) has been struggling lately, but the selling pressure may be coming to an end soon

Catalent (CTLT) Sees Hammer Chart Pattern: Time to Buy?

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that members of its executive leadership team will virtually present at the SVB Leerink 10th Annual Global Healthcare Conference at 11:20 a.m. ET on February 25, 2021. A live webcast of the presentation will be accessible at http://investor

Catalent, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference

USANA Health Sciences

USNA vs. CTLT: Which Stock Is the Better Value Option?

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), priced a private offering (the “Private Offering”) of $550 million in aggregate principal amount of 3.125% senior unsecured notes d

Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2029

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), intends to offer, subject to market and other conditions, $475 million in aggregate principal amount of senior unsecured notes due

Catalent Announces Launch of Private Offering of $475 Million of Senior Unsecured Notes Due 2029

Catalent (CTLT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why Growth Investors Shouldn't Overlook Catalent (CTLT)

Catalent, Inc. (CTLT) CEO John Chiminski on Q2 2021 Results - Earnings Call Transcript

Catalent (CTLT) delivered earnings and revenue surprises of 12.50% and 1.66%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Tops Q2 Earnings and Revenue Estimates

Shares of Catalent (NYSE:CTLT) moved higher by 1.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 40.00% year over year to $0.63, which beat the estimate of $0.55.

Catalent: Q2 Earnings Insights

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced financial results for the second quarter of fiscal 2021, which ended December 31, 2020. “Our second quarter results reflect robust organic growth in our Biologics segment, and our increased guidance reflects our expectation of continued str

Catalent, Inc. Reports Second Quarter Fiscal 2021 Results

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene and cell therapies, and consumer health products, today announced that it will release financial results for the second quarter of fiscal year 2021 ended December 31, 2020, before the market open on Tuesday, February 2, 2021. The Company's management will host a webcast to discuss the results at 8:15 a.m.

Catalent, Inc. Announces Second Quarter Fiscal Year 2021 Earnings Conference Webcast

Catalent is forming a base and near a possible buy zone ahead of its next quarterly earnings report, expected on or around Feb. 3. The post Earnings Season Preview: Catalent Near Buy Zone With EPS Due appeared first on Investor's Business Daily.

Earnings Season Preview: Catalent Near Buy Zone With EPS Due

Charles River Laboratories

Freeport-McMoRan

Northrop Grumman

Increasingly, the Wall Street firms we cover are starting to agree that while the future for the U.S.

News for Catalent Stock (CTLT)